Cell line · CVCL_0125
Papers261
1 to 20 of 261
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Integrated Computational Pipeline Combining Metabolomics and Network Pharmacology for Bioactive Scaffold Discovery: Application to Antarctic Moss Chorisodontium aciphyllum. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genetically engineered RNA inducers of proximity for protein regulation. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nanocatalytic Immunotherapy Targeting Tumor-Resident Intracellular Bacteria for Triple-Negative Breast Cancer Treatment and Metastasis Suppression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ultrasound-Activated Ce(IV)-Integrated Biomimetic Nanoplatform for Oxygenation-Reinforced Gas-Sonodynamic Ferroptosis and cGAS-STING-Driven Antitumor Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Resistance to membrane damage enhances metastatic potential of breast cancer cells via dysregulated phospholipid profiles and annexin-mediated repair. | Cell Mol Life Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Multifunctional Metal-Based Nanomedicine for Copper Sequestration, in situ Toxification, and Immune Activation Against Metastatic Cancer. | Int J Nanomedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Actinomycin Analogs From Streptomyces polyantibioticus S4D258: Structural Elucidation and Antiproliferative Activity Against Triple-Negative Breast Cancer. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synthesis and Biological Evaluation of a Lipophilic Vorinostat Prodrug. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Situ Gelling of TPZ-Loaded Nanogel for Sustained Intratumoral Delivery and Enhanced Cancer Immunotherapy. | Gels | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Macrophage polarization regulated by the βTrCP-NF-κB inflammatory signaling pathway is required for valproic acid's dual role in breast tumor radiosensitivity and normal tissue radioprotection. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AI-Assisted Tumor Boundary Delineation via Targeted Ultrasmall Iron Oxide Nanoprobe for High-Contrast HER2-Positive Tumor Imaging. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer. | Signal Transduct Target Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of tripartite neuron-cancer-immune cell crosstalk augments response to chemotherapy and immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multifunctional Near-Infrared-Responsive Silk Fibroin Nanomedicine for Tumor Treatment and Imaging. | Materials (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acetoacetate-GPR43 axis epigenetically silences IL-6/CSF1 to restrict TAMs-driven metastatic lung cancer. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0125/papers